Rona Therapeutics Receives IND Approval for Innovative Hypertension Drug RN1871
Rona Therapeutics Achieves Significant Milestone with IND Approval for RN1871
Rona Therapeutics, an emerging biotech firm specializing in RNA-based therapies, announced a monumental development in hypertension management. The company received approval from China's National Medical Products Administration (NMPA) for its Investigational New Drug (IND) application concerning RN1871. This siRNA drug targets angiotensinogen (AGT), a significant protein involved in blood pressure regulation.
The mechanics of RN1871 are particularly fascinating. By specifically silencing AGT messenger RNA (mRNA) in the liver, this therapy aims to inhibit the production of a precursor protein intricately linked to the Renin-Angiotensin-Aldosterone System (RAAS). Such a pathway is critically involved in maintaining proper blood pressure levels, and when overactive, can lead to hypertension, a condition affecting over 1.5 billion people globally.
Stella Shi, the CEO and Founder of Rona Therapeutics, expressed her enthusiasm regarding the IND approval, highlighting it as a major leap forward in tackling chronic diseases with innovative solutions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.